MabVax Therapeutics Files Suit Against Sichenzia Ross Ference LLP, a Law Firm that Formerly Represented the Company in Certain Corporate, Securities, and Securities and Exchange Commission Matters


SAN DIEGO  /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTC: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs, announced today that the Company has filed, in the Superior Court of California, County of San Diego, a complaint against a law firm that previously represented the Company in certain corporate, securities, and Securities and Exchange Commission ("SEC") matters. The complaint names the law firm, Sichenzia Ross Ference LLP, eight current partners of the firm, and one former partner of the firm, Harvey Kesner, as defendants. It asserts claims for negligent professional practice, breach of fiduciary duty, breach of contract, unjust enrichment, deceit, and fraud. The caption of the complaint is MabVax Therapeutics Holdings, Inc. v. Sichenzia Ross Ference LLP et al. The Company is evaluating additional claims it may have against others in connection with the same or similar subject matter(s).

The docket number is 37-2018-00045609-CU-PN-CTL.

Forward Looking Statements:

This press release contains "forward-looking statements" regarding a law suit filed in the Superior Court of California, County of San Diego, against a law firm and certain lawyers who previously represented the Company and other matters that are not historical facts. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "evaluating additional claims," "may," "could," "plans," "expects," "will," "potential," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. The Company cannot predict the outcome of any claims it may have against the law firm, or others. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in filings with the Superior Court of California, County of San Diego, and the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2017 and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at The parties do not undertake any obligation to update forward-looking statements contained in this press release.

MabVax Investor Contact:

Phone: 858-500-8468

Media Contact:

Russo Partners LLC
Phone: 212-845-4272


View original content to download multimedia:

SOURCE MabVax Therapeutics Holdings, Inc.

Company Codes: OTC-PINK:MBVX

Back to news